LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers
Cancers · 05.11.2024 · 16 (22) · 3725
DOI: 10.3390/cancers16223725 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 05.11.2024. Verfasst von Ugur Gezer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Epigenetic dysregulation is a hallmark of many human malignancies, with DNA methylation being a primary mechanism influencing gene expression and maintaining genomic stability. Genome-wide hypomethylation, characteristic of many cancers, is partly attributed to the demethylation of repetitive elements, including LINE-1, a prevalent non-LTR retrotransposon. The methylation status of LINE-1 is closely associated with overall genomic methylation levels in tumors. cfDNA comprises extracellular DNA fragments found in bodily fluids such as plasma, serum, and urine, offering a dynamic snapshot of the genetic and epigenetic landscape of tumors. This real-time sampling provides a minimally invasive avenue for cancer diagnostics, prognostics, and monitoring. The methylation status of LINE-1 in cfDNA has emerged as a promising biomarker, with several studies highlighting its potential in diagnosing and predicting outcomes in cancer patients. Recent research also suggests that cfDNA-based LINE-1 methylation analysis could serve as a valuable tool in evaluating the efficacy of cancer therapies, including immunotherapy. The growing clinical significance of cfDNA calls for a closer examination of its components, particularly repetitive elements like LINE-1. Despite their importance, the role of LINE-1 elements in cfDNA has not been thoroughly gauged. We aim to address this gap by reviewing the current literature on LINE-1 cfDNA assays, focusing on their potential applications in diagnostics and disease monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.
- Munich Biomarker Research Center, Institute of Laboratory Medicine, German Heart Center, Technical University Munich, 80636 Munich, Germany.
ORCID-Profile: Ugur Gezer, Emre Özgür, Stefan Holdenrieder
Zitieren
APA
Gezer, U., Özgür, E., Yörüker, E. E., Polatoglou, E., Holdenrieder, S., & Bronkhorst, A. (2024). LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers. Cancers, 16(22), 3725. https://doi.org/10.3390/cancers16223725
Vancouver
Gezer U, Özgür E, Yörüker EE, Polatoglou E, Holdenrieder S, Bronkhorst A. LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers. Cancers. 2024;16(22):3725. doi:10.3390/cancers16223725
BibTeX
@article{Gezer2024,
author = {Gezer, Ugur and Özgür, Emre and Yörüker, Ebru E and Polatoglou, Eleni and Holdenrieder, Stefan and Bronkhorst, Abel},
title = {LINE-1 cfDNA Methylation as an Emerging Biomarker in Solid Cancers},
journal = {Cancers},
year = {2024},
volume = {16},
number = {22},
pages = {3725},
doi = {10.3390/cancers16223725}
}
EUVIMED